Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I own a chit ton...looking to wake up one morning and see a 50% gap up and you talking about #1 spot on barcharts....it's coming......
SIGA 11.25 looking to break up out of channel....
looks a tad thinner today....
had my ass handed to me so far this round..... so I keep buying....
gapper....bout time.....
SIGA +6% on a tough day...
I remember reading that the half empty silos could hold most of this years wheat but corn would be left in the ground as there will be nowhere to put it....
YUP....
link back....
GTSM backing off....don't see that everyday.....
CSTI and GTSM showing no size but soaking it all up on bid......
7.66 million available to trade........think about it....let's have some fun ....
Share Structure
Market Cap Market Cap
282,212,008
06/14/2022
Authorized Shares
350,000,000
06/14/2022
Outstanding Shares
235,176,673
06/14/2022
Restricted
219,673,603
06/14/2022
Unrestricted
15,503,070
06/14/2022
Held at DTC
7,663,544
06/14/2022
Float
Not Available
very nice.....I just get frustrated.......if people would just stop wacking..... the ask would get hammered......so simple
I don't see how this doesn't go to $5 today
have you never watched the way some of the geniuses here trade ?...lol
https://www.bnnbloomberg.ca/who-to-convene-emergency-meeting-on-monkeypox-amid-rising-spread-1.1779113
When the WHO declared the coronavirus a PHEIC in January 2020, there were fewer than 100 cases, two infections outside China, and no deaths.
over 1800 monkey pox cases right now.....
BVNRY 9.33 Bavarian Nordic vaccine
SIGA 10.51 TPOXX®, also known as tecovirimat antiviral
What's the monkeypox vaccine and who should get it
Nicole Ireland · CBC News · Posted: Jun 15, 2022 4:00 AM ET | Last Updated: 4 hours ago
A health-care worker prepares a syringe at a monkeypox vaccination clinic run by public health authorities in Montreal. (Christinne Muschi/Reuters)
As the number of confirmed monkeypox cases continues to rise in Canada, infectious disease and public health experts are providing vaccinations to those at risk of infection.
Since monkeypox and smallpox are both part of the orthopox family of viruses, experts say some vaccines will work against both.
But the vaccines being recommended for use against monkeypox today are different from those used in the last century's global effort to eradicate smallpox, the World Health Organization (WHO) says.
"Some countries have maintained strategic supplies of older smallpox vaccines from the Smallpox Eradication Programme (SEP) which concluded in 1980," said the WHO's interim monkeypox vaccination guidance issued on Tuesday.
"These first-generation vaccines held in national reserves are not recommended for monkeypox at this time, as they do not meet current safety and manufacturing standards."
Monkeypox causes flu-like symptoms and skin lesions, and spreads through close contact.
Both WHO and Canada's National Advisory Committee on Immunization (NACI) have now released guidelines on what vaccine to use against monkeypox, and who might benefit from it.
What monkeypox vaccine is available in Canada?
The vaccine approved for immunization against monkeypox in Canada is MVA-BN, or Modified Vaccinia Ankara - Bavarian Nordic. Bavarian Nordic, headquartered in Denmark, is the company that manufactures it.
In Canada, the vaccine has the trade name Imvamune. (It's called Imvanex in the European Union and Jynneos in the U.S.)
Imvamune was originally authorized in Canada for "extraordinary use" against smallpox in November 2013, as part of the federal government's emergency plan to immunize people if the deadly disease were ever to resurface. In 2020, Canada expanded the vaccine's authorization to include immunization against monkeypox, NACI documents say.
An employee of the vaccine company Bavarian Nordic works in one of its laboratories near Munich, Germany, on May 24. The company's Imvamune vaccine is approved in Canada for immunization against monkeypox. (Lukas Barth/Reuters)
Routine smallpox vaccinations stopped in Canada in the early 1970s. But because the viruses are related, those smallpox vaccinations may have provided some degree of immunity against monkeypox as well, experts say.
"It's likely that this, you know, mass immunization campaign for smallpox really kept monkeypox in check for many years," said Dr. Isaac Bogoch, an infectious diseases specialist at Toronto General Hospital.
But most people under 50 in Canada didn't get that protection — and that might be one of the reasons we're seeing monkeypox now, he said.
How is Imvamune different from the old-school smallpox vaccine?
Imvamune contains a weakened strain of the vaccinia virus, which provokes the immune response to fight off smallpox and monkeypox.
Unlike the original smallpox vaccine, this weakened virus is non-replicating, meaning it can't make copies of itself.
Early-generation vaccines based on replicating vaccinia strains led to unpleasant side effects for some and could be problematic for people who were immunocompromised, said Dr. Zain Chagla, an infectious disease specialist at McMaster University in Hamilton.
In addition, older generations of smallpox vaccine are administered differently. Instead of a regular syringe, the health-care provider uses a "bifurcated needle" with two prongs and pricks the skin repeatedly to get the dose in.
Who should consider vaccination against monkeypox?
Infectious disease specialists say, right now, monkeypox is not affecting the majority of the general Canadian population, although anyone can get the virus if they're in close physical contact with someone who is infected.
The LGBTQ community, particularly men who have sex with men, are at disproportionate risk of infection in this outbreak, they say. Health-care workers or lab workers who work directly with orthopoxviruses could also be at risk.
Quebec expands monkeypox vaccination efforts as virus continues to spread
World Health Organization holding emergency session next week on monkeypox
As a result, experts say monkeypox vaccinations should be offered to those at-risk populations as a preventative measure. The vaccine can also be offered to those who have already been exposed to someone with monkeypox — known as post-exposure prophylaxis.
In both cases, monkeypox immunization outreach needs to be targeted, they say.
"This is not a widespread vaccine for everyone; it is risk-based vaccination," Chagla said.
Bogoch agreed.
"I don't think we're anywhere near starting, you know, vaccine campaigns for the general public," he said.
"At this point in time, this should be a very focused and targeted vaccine campaign for people who have been exposed and for people who are at the highest risk of getting this infection."
How many doses?
Both the WHO and NACI recommend two doses of Imvamune, given 28 days apart.
A possible exception, according to NACI's guidance, is someone who has had a smallpox vaccination in the past. In that case, they could be given just one dose to act as a booster.
Are there any potential allergens in the vaccine?
Yes. NACI says Imvamune includes the following ingredients:
Traces of residual host (egg) cell DNA and protein.
Tromethamine (Trometamol, Tris).
Benzonase.
Gentamicin and ciprofloxacin.
https://www.cbc.ca/news/health/monkeypox-smallpox-vaccine-imvamune-1.6488917
WHO convenes experts to decide if monkeypox is an emergency
The World Health Organization will convene its emergency committee to determine if the monkeypox outbreak that has mysteriously spread beyond Africa warrants being declared a global health emergency
ByJamey Keaten Associated Press
June 14, 2022, 12:25 PM
The extremely rare disease is slowly making its way around the world; here’s what to look out for.
GENEVA -- The World Health Organization will convene an emergency committee of experts to determine if the expanding monkeypox outbreak that has mysteriously spread outside Africa should be considered a global health emergency.
WHO Director-General Tedros Adhanom Ghebreyesus said Tuesday he decided to convene the emergency committee on June 23 because the virus has shown “unusual” recent behavior by spreading in countries well beyond parts of Africa where it is endemic.
“We believe that it needs also some coordinated response because of the geographic spread,” he told reporters.
Declaring monkeypox to be an international health emergency would give it the same designation as the COVID-19 pandemic and mean that WHO considers the normally rare disease a continuing threat to countries globally.
The U.K. said Monday it had 470 cases of monkeypox across the country, with the vast majority in gay or bisexual men. British scientists said last week they could not tell if the spread of the disease in the U.K. had peaked.
Recent Stories from ABC News
The meeting of outside experts could also help improve understanding and knowledge about the virus, Tedros said, as WHO released new guidelines about vaccinating against monkeypox.
Dr. Ibrahima Soce Fall, WHO’s emergencies director for Africa, said case counts were growing every day and health officials face “many gaps in terms of knowledge of the dynamics of the transmission” — both in Africa and beyond.
“With the advice from the emergency committee, we can be in a better position to control the situation. But it doesn’t mean that we are going straight to a public health emergency of international concern,” he said, referring to WHO's highest level of alert for viral outbreaks. “We don’t want to wait until the situation is out of control to start calling the emergency committee.”
The U.N. health agency does not recommend mass vaccination, but advises the “judicious” use of vaccines. It said controlling the disease relies primarily on measures like surveillance, tracking cases and isolating patients.
Last month, a leading adviser to WHO said the outbreak in Europe and beyond was likely spread by sex at two recent rave parties in Spain and Belgium.
Scientists warn that anyone, regardless of sexual orientation, is susceptible to catching monkeypox if they are in close, physical contact with an infected person or their clothing or bed sheets.
WHO has been working with partner countries to create a mechanism by which some vaccines for smallpox — a related disease — might be made available to countries that are affected, as research continues into their effectiveness against the new outbreak.
Tedros said more than 1,600 cases and nearly 1,500 suspected cases have been reported this year in 39 countries, including seven where monkeypox has been reported for years. A total of 72 deaths have been reported but none in the newly affected countries, which include Britain, Canada, Italy, Poland, Spain and the United States.
The ongoing outbreak of monkeypox in Europe and elsewhere marks the first time the disease has been known to spread among people who have no travel links to Africa.
https://abcnews.go.com/Health/wireStory/convenes-experts-decide-monkeypox-emergency-85384577
WHO convenes experts to decide if monkeypox is an emergency
The World Health Organization will convene its emergency committee to determine if the monkeypox outbreak that has mysteriously spread beyond Africa warrants being declared a global health emergency
ByJamey Keaten Associated Press
June 14, 2022, 12:25 PM
GENEVA -- The World Health Organization will convene an emergency committee of experts to determine if the expanding monkeypox outbreak that has mysteriously spread outside Africa should be considered a global health emergency.
WHO Director-General Tedros Adhanom Ghebreyesus said Tuesday he decided to convene the emergency committee on June 23 because the virus has shown “unusual” recent behavior by spreading in countries well beyond parts of Africa where it is endemic.
“We believe that it needs also some coordinated response because of the geographic spread,” he told reporters.
Declaring monkeypox to be an international health emergency would give it the same designation as the COVID-19 pandemic and mean that WHO considers the normally rare disease a continuing threat to countries globally.
The U.K. said Monday it had 470 cases of monkeypox across the country, with the vast majority in gay or bisexual men. British scientists said last week they could not tell if the spread of the disease in the U.K. had peaked.
Recent Stories from ABC News
The meeting of outside experts could also help improve understanding and knowledge about the virus, Tedros said, as WHO released new guidelines about vaccinating against monkeypox.
Dr. Ibrahima Soce Fall, WHO’s emergencies director for Africa, said case counts were growing every day and health officials face “many gaps in terms of knowledge of the dynamics of the transmission” — both in Africa and beyond.
“With the advice from the emergency committee, we can be in a better position to control the situation. But it doesn’t mean that we are going straight to a public health emergency of international concern,” he said, referring to WHO's highest level of alert for viral outbreaks. “We don’t want to wait until the situation is out of control to start calling the emergency committee.”
The U.N. health agency does not recommend mass vaccination, but advises the “judicious” use of vaccines. It said controlling the disease relies primarily on measures like surveillance, tracking cases and isolating patients.
Last month, a leading adviser to WHO said the outbreak in Europe and beyond was likely spread by sex at two recent rave parties in Spain and Belgium.
Scientists warn that anyone, regardless of sexual orientation, is susceptible to catching monkeypox if they are in close, physical contact with an infected person or their clothing or bed sheets.
WHO has been working with partner countries to create a mechanism by which some vaccines for smallpox — a related disease — might be made available to countries that are affected, as research continues into their effectiveness against the new outbreak.
Tedros said more than 1,600 cases and nearly 1,500 suspected cases have been reported this year in 39 countries, including seven where monkeypox has been reported for years. A total of 72 deaths have been reported but none in the newly affected countries, which include Britain, Canada, Italy, Poland, Spain and the United States.
The ongoing outbreak of monkeypox in Europe and elsewhere marks the first time the disease has been known to spread among people who have no travel links to Africa.
https://abcnews.go.com/Health/wireStory/convenes-experts-decide-monkeypox-emergency-85384577
merge in a New York deli
I like me a nice deli sam'ich......
agree on all counts....nice gains coming down the road but patience will be required while the powers that be get the shares distributed to their benefit .....it's coming.....imho
. And more then likely would be able to get in under .15 again after the split . So unless that 300% profit is locked in it only looks cool on paper .
correct...and I will be able to sell you 3 by then.....agree about the profits though,,,... sell button is your friend...
ahh...and here I thought it meant you're a cuddler too...lmao
wat up....you must be buying too....
Stoked I didnt listen to the experts and buy into the goff pink current pile of hoot at 70 cents
you stoked you didn't listen at .15 either ?....lol
looks like cover day to me.....news must be coming....
filled more in .006's ..have more bids lower if you want out.....
just bought this for the tomatoes.....(smh)
I followed the bouncing Tom......
Under the agreement, Meridian will promote the sale of oral TPOXX for the treatment of smallpox in all markets, except for the United States and South Korea. SIGA will continue to be the owner of all rights in the U.S. market.
then....
https://altariscap.com/altaris-acquires-meridian-medical-technologies-from-pfizer/
so now we have a guy who has sold TPOXX all over the world and can turn to his new bosses with their Billions and say "you guys should really buy SIGA"...?
have some bids lower as well....don't think I want to fill those...lol
PALT wouldn't surprise me...
been grabbing .0072 's lately..... a lottery ticket for the future....
PALT...it's doing the Mark slow grindy thing...
SIGA.....next PR blows it open....
PALT faded before the open so I went with COGT
of course you did.....we all know you never lose.....
SIGA 10.66
and down it goes....ARCA pretty aggressively shorting....
would be sweet if this is the last of the Canadian overhang showing here on L2....
people starting to realize this is the ONLY vaccine countries want to use....
Bavarian Nordic Enters Additional Vaccine Contracts with Governments in Response to Monkeypox Outbreak
Bavarian Nordic A/S
Mon, May 30, 2022, 2:04 p.m.·4 min read
Bavarian Nordic A/S
Bavarian Nordic A/S
A number of contracts of varying size have been signed
Deliveries to start immediately aiming to ensure a rapid response to the current monkeypox outbreak
Company upgrades its financial guidance for 2022
COPENHAGEN, Denmark, May 30, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the signing of a number of supply contracts with undisclosed countries for the Company’s smallpox vaccine with the aim to ensure sufficient supply to meet the requirements for vaccinating individuals at risk for monkeypox in the short to medium term. The vaccine is approved for use against monkeypox by the U.S. Food and Drug Administration and Health Canada as the only vaccine having obtained regulatory approval for this indication in any territory.
While the terms of the agreements remain undisclosed, the sum of these orders will positively impact the Company’s financial guidance for 2022 as explained below.
Bavarian Nordic is currently in dialogue with additional countries concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness. In this unprecedented situation, the Company is making every possible effort to ensure sufficient availability of vaccines to meet the current demand.
Paul Chaplin, President and CEO of Bavarian Nordic said: “The current monkeypox outbreak continues to call for a swift and coordinated response from health authorities, and we are pleased to assist more countries with supply of vaccines while we continue our dialogues with other governments to make vaccines available as fast as possible to mitigate the situation.”
As a consequence of these orders, Bavarian Nordic raises its expectations for the financial results for 2022 with revenue now expected to be between DKK 1,400 and 1,600 million (previously between DKK 1,300 and 1,500 million), EBITDA expectations raised to a loss between DKK 900 and 1,100 million (previously a loss between DKK 1,000 and 1,200 million) and cash and cash equivalents at year-end now between DKK 1,200 and 1,300 million (previously between DKK 1,100 and 1,200 million). The guidance reflects the significant investments in research and development being made in 2022 to advance the Company’s two lead product candidates: a vaccine against respiratory syncytial virus (RSV) and a booster vaccine against COVID-19 into Phase 3 clinical trials.
About the smallpox/monkeypox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. The vaccine was approved by the European Commission in 2013 for immunization against smallpox in adults aged 18 years and older and has subsequently gained regulatory approvals in Canada and the U.S. where the approval has been extended to include the monkeypox indication as the only vaccine having obtained this to-date.
Bavarian Nordic has ongoing supply contracts with USA and Canada and has delivered the vaccine to a number of undisclosed countries globally as part of their national biological preparedness. In recent years, the vaccine has been supplied in response to sporadic cases of monkeypox.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 21 / 2022
Attachment
2022-21-en
https://ca.news.yahoo.com/bavarian-nordic-enters-additional-vaccine-180400029.html
nice bids in again....they will run out of share eventually ....